Shire/New River NRP104 submission
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Shire and New River are seeking a pediatric indication for children ages six to 12 for the attention deficit/hyperactivity disorder therapy NRP104. New River submitted an NDA for the amphetamine prodrug Dec. 6, giving FDA an Oct. 6, 2006 standard review action date. Lower abuse liability is one of the key advantages the sponsors hope to claim vis-à-vis currently marketed stimulant ADHD agents. The firms reported positive Phase III data for the new molecular entity in May (Pharmaceutical Approvals Monthly June 2005, In Brief)...
You may also be interested in...
New River NRP104 Phase III data
New River's d-amphetamine prodrug NRP104 showed statistically significant results for primary and secondary endpoints in a Phase III study of children with attention deficit hyperactivity disorder, the firm reports May 23. The study of 285 patients aged six to 12 showed that each of three doses of NRP104 had a significant outcome for the ADHD Rating Scale (primary) and the Conners Parent Rating Scale (p<0.0001), New River said. New River is collaborating with Shire on NRP104; the firms signed a global commercialization deal in January. NRP104 is expected to reach the market by 2006 (1Pharmaceutical Approvals Monthly February 2005, p. 19)...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.